<DOC>
	<DOCNO>NCT00001339</DOCNO>
	<brief_summary>Patients response preoperative chemotherapy residual disease follow surgery Regimen A treat Regimen B postoperatively . The following acronym use : DDD Mitotane , NSC-38721 DOX Doxorubicin , NSC-123127 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 Regimen A : 4-Drug Combination Chemotherapy follow Surgery follow 4-Drug Combination Chemotherapy . DDD/DOX/VCR/VP-16 ; follow surgical debulking ; follow DDD/DOX/VCR/VP-16 . Regimen B : Single-Agent Chemotherapy . DDD .</brief_summary>
	<brief_title>A Study Combination Chemotherapy Surgical Resection Treatment Adrenocortical Carcinoma : Continuous Infusion Doxorubicin , Vincristine Etoposide With Daily Mitotane Before After Surgical Resection</brief_title>
	<detailed_description>This study infusional doxorubicin , vincristine , etoposide combination daily oral mitotane patient adrenocortical cancer . Although mitotane use extensively adrenocortical cancer document single agent activity , limited experience available use mitotane combination chemotherapy . In trial primary reason use mitotane attempt enhance therapeutic efficacy , base documented in-vitro activity antagonist P-glycoprotein . The goal study determine efficacy therapy treat patient consider candidate surgical resection presentation follow response therapy . Following chemotherapy , patient deem surgical candidate undergo surgical resection evaluation response . Patients respond chemotherapy resume combination treatment surgery . Patients respond maintain single agent mitotane deem ineffective .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Mitotane</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Biopsyproven primary recurrent adrenocortical carcinoma consider surgically resectable presentation potentially resectable follow initial response chemotherapy . Potentially resectable disease include primary lesion , nodal metastasis , liver lung metastasis limit size number . Patients surgical resection consider unlikely may enter discretion investigator . Measurable disease presentation require . A life expectancy least 3 month performance status ( Karnofsky scale ) 70 percent great . Prior chemotherapy allow , however , patient receive chemotherapy four week presentation . Patients receive prior doxorubicin may enrol provide meet entry criterion ejection fraction great 40 percent determine MUGA scan . Prior mitotane therapy allow . A dose 3 gm/day tolerate least one week . Patients need mitotane therapy prior start protocol . WBC great 3,000/mm ( 3 ) ; Platelet count great 100,000/mm ( 3 ) ; Creatinine clearance great 50 ml/min ; bilirubin less 1.5 mg/dl ; serum transaminase less 2 time normal . Patient good surgical candidate . Must sign inform consent geographically accessible return follow treatment . No presence second malignancy , squamous cell carcinoma skin . No active systemic infection . Must currently receive treatment discontinue follow agent : diltiazem , nicardipine , phenothiazine , phenytoin , terfenadine verapamil . No positive serology HIV . No positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Multidrug Resistance</keyword>
	<keyword>Reversal Drug Resistance</keyword>
	<keyword>P-Glycoprotein</keyword>
	<keyword>MDR-1</keyword>
</DOC>